Cancer drugs and QT prolongation: weighing risk against benefit

Expert Opin Drug Saf. 2017 Oct;16(10):1099-1102. doi: 10.1080/14740338.2017.1354987. Epub 2017 Jul 20.

Authors

Pierantonio Menna¹, Emanuela Salvatorelli¹, Giorgio Minotti¹

Affiliation

¹ a Department of Medicine and Unit of Drug Sciences , University Campus Bio-Medico of Rome , Italy.

PMID: 28699784
DOI: 10.1080/14740338.2017.1354987

No abstract available

Keywords: Cancer drugs; QT prolongation; comorbidities; risk:benefit ratio.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacology
Electrocardiography
Humans
Long QT Syndrome / chemically induced*
Neoplasms / drug therapy
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / pharmacology

Substances

Antineoplastic Agents
Protein Kinase Inhibitors